Blue Sky
 Top Line
HomeFeedback
About Lilly

Who We Are

Eli Lilly and Company is a global research-based pharmaceutical corporation dedicated to creating and delivering innovative pharmaceutical-based health care solutions that enable people to live longer, healthier and more active lives.

Our research and development efforts target health care solutions that address urgent, unmet medical needs and replace more expensive and invasive medical treatments. As we pursue leadership in the therapeutic areas where we are focusing our resources, we often reduce the cost of disease, thereby creating significant value for patients, health care providers and payers, and health care policymakers.

Lilly employs 31,100 people worldwide and markets its products in 159 countries.

Our Values

As we implement our strategies and pursue our objectives, long-established core values guide us in all that we do:

  • Respect for people that includes our concern for the interests of all the people worldwide who touch -- or are touched -- by our company: customers, employees, shareholders, partners and communities

  • Integrity that embraces the very highest standards of honesty, ethical behavior and exemplary moral character

  • Excellence that is reflected in our continuous search for new ways to improve the performance of our business in order to become the best at what we deliver.

What We Do

At Lilly, we are focusing on the discovery and development of the most effective pharmaceutical-based health care solutions for our diverse customers throughout the world. We are dramatically accelerating our drug discovery and development processes and, thus, the speed at which our new products achieve regulatory approval and reach patients.

With our pharmaceutical business central to our efforts to provide customers with the best clinical and economic outcomes, we seek constant innovation through the creative combination of scientific discovery and the application of information technology. This continual search for innovation underpins our efforts not only in the laboratory but throughout the entire Lilly organization.

As Lilly touches the lives of people worldwide, we recognize that we have a particular responsibility to be a good corporate citizen of the communities in which we operate and to help preserve the environment for the generations to come.

Major Facilities

Research and development facilities are located in Australia*, Belgium, Canada, England, Germany, Japan, Singapore*, Spain and the United States. Clinical studies are conducted in more than 30 countries worldwide.

Lilly manufacturing facilities are located in Australia, Brazil, China*, Egypt*, England, France, Germany, Hungary*, Ireland, Italy, Japan, Korea*, Mexico, Pakistan*, Poland*, Puerto Rico, South Africa, Spain, Taiwan, the United States and Venezuela.

* joint venture

Financial Information

Financials -- 1997

(dollars in millions, except per-share data)

Net sales
Net income -- normalized*
Earnings per share -- normalized*
Net income (loss) -- as reported
Earnings (loss) per share -- as reported
Dividends paid per share
Capital expenditures
Economic value added (EVA)
 $8,517.6
$1,774.4
$1.57
$(385.1)
$(0.35)
$0.74
$366.3
$751
Research and Development
1997 Expenditures
$1,382.0 million/year
$115.2 million/month
$26.6 million/week
$5.3 million/workday
Increase from previous year
R&D as a percentage of sales
Total R&D investment in last five years from continuing operations
  
 
 
 
 
16%
16%
$5,207.5 million